Darnestown, MD, United States of America

Leslie Sydnor Johnson

USPTO Granted Patents = 125 (Patent Applications = 40)

CIPO Patents = 22 (Patent Applications = 21)

EPO Patents = 42 (Patent Applications = 54)

Average Co-Inventor Count = 3.4

ph-index = 27

Forward Citations = 2,291(Granted Patents)

Forward Citations (Not Self Cited) = 1,708(Dec 10, 2025)

Inventors with similar research interests:

Location History:

New York City, NY (US) (2000)
Germantown, MD (US) (2003 - 2012)
Darnstown, MD (US) (2010 - 2020)
Damestown, MD (US) (2017 - 2020)
Darnestown, MD (US) (2005 - 2023)
Rockville, MD (US) (2020 - 2024)
Damestoen, MD (US) (2024)

Company Filing History:

University of Texas System

patents

4. 6 out of 1,535

Boehringer Ingelheim International Gmbh

Bowie State University

patents

7. 2 out of 260

St. Jude Children's Research Hospital

patents

8. 2 out of 1,270

The University of North Carolina at Chapel Hill

12. 3 out of 832,718

Other

patents

where one patent can have more than one assignee

Years Active: 2000-2024

Loading Chart...

Areas of Expertise:

Bispecific Molecules

Cd3-Binding Molecules

HER2/neu-Specific Antibodies

Tri-Specific Binding Molecules

Pd-1-Binding Molecules

Lag-3-Binding Molecules

Antibody Drug Conjugates

Covalent Diabodies

Il-23A Targeting Compounds

Tumor Antigens

B7-H3 Binding Molecules

Multi-Chain Polypeptides

125 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12173051 - Bispecific molecules comprising an HIV-1 envelope targeting arm (2024-12-24),

2. 12049501 - CD3-binding molecules capable of binding to human and non-human CD3 (2024-07-30),

3. 12024569 - HER2/neu-specific antibodies and methods of using same (2024-07-02),

4. 11942149 - Bispecific binding molecules that are capable of binding CD137 and tumor antigens, and uses thereof (2024-03-26),

5. 11884744 - Compound targeting IL-23A and B-cell activating factor (BAFF) and uses thereof (2024-01-30),

6. 11858991 - LAG-3-binding molecules and methods of use thereof (2024-01-02),

7. 11840571 - Methods of using bispecific molecules having immunoreactivity with PD-1 and CTLA-4 (2023-12-12),

8. 11820818 - Multi-chain polypeptide-containing tri-specific binding molecules (2023-11-21),

9. 11795226 - Bispecific CD16-binding molecules and their use in the treatment of disease (2023-10-24),

10. 11697684 - Tri-specific binding molecules that specifically bind to multiple cancer antigens (2023-07-11),

11. 11685781 - Variant CD3-binding domains and their use in combination therapies for the treatment of disease (2023-06-27),

12. 11680096 - Compound targeting IL-23A and TNF-alpha and uses thereof (2023-06-20),

13. 11639386 - Bi-specific monovalent diabodies that are capable of binding CD19 and CD3, and uses thereof (2023-05-02),

14. 11623959 - PD-1-binding molecules and methods of use thereof (2023-04-11),

15. 11591400 - B7-H3 directed antibody drug conjugates (2023-02-28),

Sure, I can help you with that. Here is the article:

Title: Leslie Sydnor Johnson: Trailblazing Inventor in Biomedical Innovations

Introduction:

Leslie Sydnor Johnson, a prolific inventor based in Darnestown, MD, is a beacon of innovation in the field of biomedical science. With an impressive portfolio of 121 patents to her name, Leslie exemplifies the intersection of passion, dedication, and excellence in the world of inventions.

Latest Patents:

Leslie's latest patents showcase her groundbreaking work in developing bispecific binding molecules capable of binding CD137 and tumor antigens. These innovative molecules hold immense potential for the treatment of cancer and other diseases. Additionally, her inventions include LAG-3-binding molecules that play a crucial role in stimulating immune responses.

Career Highlights:

Throughout her illustrious career, Leslie Sydnor Johnson has made significant contributions to the field of biomedicine. Having worked at renowned companies such as MacroGenics, Inc. and MedImmune Limited, she has been at the forefront of cutting-edge research and development in the pharmaceutical industry.

Collaborations:

Leslie's impactful work has been enriched by collaborations with esteemed colleagues such as Ling Ling Huang and Ezio Bonvini. Together, they have synergized their expertise to drive innovation and push the boundaries of scientific discovery.

Conclusion:

Leslie Sydnor Johnson's unwavering commitment to pioneering inventions underscores her status as a trailblazer in the realm of biomedical innovations. Her remarkable achievements not only inspire aspiring inventors but also exemplify the transformative power of human ingenuity in addressing critical healthcare challenges.

This text is generated by artificial intelligence and may not be accurate.